Share Price $13.00
Shares Offered 5,500,000
Offer Amount $71,500,000.00
Total Expenses $3,050,000.00
Shares Outstanding 24,879,574
They are a leading gene therapy platform company focused on discovering and
developing new therapeutic products for people living with rare diseases
associated with the liver and caused by genetic mutations. Our initial programs
address hemophilia B, hemophilia A, ornithine transcarbamylase, or
deficiency, and glycogen storage disease type Ia, or GSDIa. In August 2015, we
submitted an Investigational New Drug application, or IND, with the U.S. Food
and Drug Administration, or FDA, for our lead product candidate, DTX101 for the
treatment of hemophilia B. In September 2015, we received notification allowing
us to proceed with our Phase I/II clinical trial of DTX101. DTX101 was also
granted Orphan Drug Designation in the United States in August 2015 and Fast
Track Designation in September 2015 for the treatment of hemophilia B. We plan
to initiate clinical trials for DTX101 by the end of 2015. We retain the global
rights to all of our programs, with the exception of our hemophilia A program,
which is partnered with Bayer HealthCare LLC, or Bayer.